Beyond CPAP: Apnimed’s Potential To Transform Sleep Apnea Management

 
• By David Wild

Boston-area biotech Apnimed expects Phase III readouts for its obstructive sleep apnea combination drug by May. Patients with OSA are desperate for a pill to treat the condition, and GLP-1 agonists are only part of the solution.

Apnimed's two Phase III trials of its obstructive sleep apnea candidate will read out mid-2025 (Shutterstock)

More from Market Intelligence

More from Leadership